momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: George G who wrote (11980)	12/22/2018 10:55:50 AM
From: tuck	Read Replies (2) of 12215

RETA as crap. I think long term use of bardoxolone will reveal safety problems that the recent trials have been too short to show. I have a hard time believing they adjusted the dosing to make those go away. But they seem to have secured accelerated approval, so it will be several years before the idea of taking it off the market is floated. They have fiddled with the data a bit. I suppose it's possible they are the one company that recently managed to screen exactly the right patients. I'm still puzzled at how the latest safety data was so remarkably clean. Speaking as a burned short, so admittedly a bit biased. See Analysis of Bardoxolone program for background, though it's now a bit dated. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next